Literature DB >> 6327822

Human T lymphocyte activation by monoclonal antibodies; OKT3, but not UCHT1, triggers mitogenesis via an interleukin 2-dependent mechanism.

J P Van Wauwe, J G Goossens, P C Beverley.   

Abstract

OKT3 and UCHT1 monoclonal antibodies, which recognize the same human T cell surface antigen, induce proliferation in T lymphocytes. In this report, we compared the mechanism by which these antibodies trigger DNA synthesis in human peripheral blood mononuclear cell (PBMC) cultures. Whereas PBMC from all donors tested were mitogenically inducible by OKT3, cells from only 25 of 40 donors were responsive to UCHT1 . UCHT1 treatment of PBMC from responders, but not from nonresponders, resulted in the expression by T cells of membrane binding sites reactive with anti-Tac monoclonal antibody, which specifies the human interleukin 2 (IL 2) receptor. UCHT1 -induced PBMC supernatants from nonresponders, but unexpectedly, also from responders, contained no measurable IL 2 activity. In keeping with this finding, anti-Tac monoclonal antibody failed to suppress UCHT1 -triggered [3H]thymidine incorporation into PBMC from responsive donors. By contrast, OKT3 treatment of PBMC from all donors led to the emergence of IL 2 receptors, and substantial IL 2 production, and the resultant DNA synthesis was inhibitable by anti-Tac antibody. These data indicate that the interaction of OKT3 and UCHT1 monoclonal antibodies with the same T cell structure leads to the induction of proliferation via two different mechanisms: one dependent on the availability of IL 2 (OKT3) and one independent on the production and processing of this lymphokine ( UCHT1 ). PBMC unresponsiveness to UCHT1 could therefore not be related to a dysfunction in IL 2 synthesis or IL 2 receptor display.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327822

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Cancer therapy with bispecific antibodies: Clinical experience.

Authors:  Archana Thakur; Lawrence G Lum
Journal:  Curr Opin Mol Ther       Date:  2010-06

Review 2.  The role of OKT3 in clinical transplantation.

Authors:  D J Norman; M R Leone
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

3.  Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells.

Authors:  Jacob R Petersburg; Jingjing Shen; Clifford M Csizmar; Katherine A Murphy; Justin Spanier; Kari Gabrielse; Thomas S Griffith; Brian Fife; Carston R Wagner
Journal:  ACS Nano       Date:  2018-06-04       Impact factor: 15.881

4.  Role of monocytes in anti-CD3-induced T-cell DNA synthesis: effect of chloroquine and monensin on anti-CD3-induced human T-cell activation.

Authors:  B Vayuvegula; K Ohira; S Gollapudi; S Gupta
Journal:  J Clin Immunol       Date:  1990-09       Impact factor: 8.317

5.  T cell response to anti-CD3 antibody in Down's syndrome.

Authors:  A Bertotto; C Arcangeli; S Crupi; I Marinelli; R Gerli; R Vaccaro
Journal:  Arch Dis Child       Date:  1987-11       Impact factor: 3.791

6.  Role of the Bp35 cell surface polypeptide in human B-cell activation.

Authors:  E A Clark; G Shu; J A Ledbetter
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

7.  Synergy in antigen presentation by thyroid epithelial cells and monocytes from patients with Graves' disease.

Authors:  K Eguchi; T Otsubo; Y Kawabe; C Shimomura; Y Ueki; H Nakao; H Tezuka; M Matsunaga; T Fukuda; N Ishikawa
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

8.  Poor induction of interleukin-2 receptor expression on CD8bright+ cells in whole blood cell cultures with CD3 mAb. Implications for immunotherapy with CD3 mAb.

Authors:  R A Janssen; A A Heijn; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

9.  The quality of chimpanzee T-cell activation and simian immunodeficiency virus/human immunodeficiency virus susceptibility achieved via antibody-mediated T-cell receptor/CD3 stimulation is a function of the anti-CD3 antibody isotype.

Authors:  Frederic Bibollet-Ruche; Brett A McKinney; Alexandra Duverger; Frederic H Wagner; Aftab A Ansari; Olaf Kutsch
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

10.  Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection.

Authors:  J J Fung; A J Demetris; K A Porter; S Iwatsuki; R D Gordon; C O Esquivel; R Jaffe; A Tzakis; B W Shaw; T E Starzl
Journal:  Nephron       Date:  1987       Impact factor: 2.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.